<html lang="en">
<head>
<meta charset="utf-8"/>
<title offset="1237">Tachyphylaxis</title>
<script src="https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_SVG.js" type="text/javascript">
</script>
</head>
<body>
<h1>Tachyphylaxis</h1>
<hr>'''Tachyphylaxis''' ([[Greek language|Greek]] ταχύς, ''tachys'', "rapid", and φύλαξις, '
<p>'phylaxis'', "protection") is a medical term describing an acute (sudden) decrease in the <a href="drug_tolerance" title="wikilink">response</a> to a drug after its administration.<a class="footnoteRef" href="#fn1" id="fnref1"><sup>1</sup></a> It can occur after an initial dose or after a series of small doses. Increasing the dose of the drug may be able to restore the original response.<a class="footnoteRef" href="#fn2" id="fnref2"><sup>2</sup></a> This can sometimes be caused by depletion or marked reduction of the amount of neurotransmitter responsible for creating the drug's effect, or by the depletion of receptors available to which the drug or neurotransmitter can bind. This depletion is caused by the cells reducing the number of receptors in response to their saturation. Some examples include <a class="uri" href="ephedrine" title="wikilink">ephedrine</a> and <a class="uri" href="MDMA" title="wikilink">MDMA</a> which act indirectly through the release of neurotransmitters, or amphetamines which act both through direct and indirect release of neurotransmitters.</p>
<h2 id="characteristics">Characteristics</h2>

<p>Tachyphylaxis is characterized by the rate sensitivity: the response of the system depends on the rate with which a stimulus is presented. To be specific, a high-intensity prolonged stimulus or often-repeated stimulus may bring about a diminished response also known as desensitization.</p>
<h3 id="molecular-interaction">Molecular interaction</h3>

<p>In biological sciences, molecular interactions are the physical bases of the operation of the system. The control of the operation, in general, involves interaction of a stimulus molecule with a receptor/enzyme subsystem by, typically, binding to the macromolecule A and causing an activation or an inhibition of the subsystem by forming an activated form of the macromolecule B. The following schematic represents the activity:</p>

<p>

<math display="inline" id="Tachyphylaxis:0">
 <semantics>
  <mrow>
   <mi>A</mi>
   <mover accent="true">
    <mo>→</mo>
    <mrow>
     <mpadded lspace="10pt" width="+10pt">
      <mi>p</mi>
     </mpadded>
    </mrow>
   </mover>
   <mi>B</mi>
  </mrow>
  <annotation-xml encoding="MathML-Content">
   <apply>
    <apply>
     <cerror>
      <csymbol cd="ambiguous">fragments</csymbol>
      <csymbol cd="unknown">p</csymbol>
      <ci>normal-</ci>
     </cerror>
     <ci>normal-→</ci>
    </apply>
    <ci>A</ci>
    <ci>B</ci>
   </apply>
  </annotation-xml>
  <annotation encoding="application/x-tex">
   A\xrightarrow{\ \ p\ \ }B
  </annotation>
 </semantics>
</math>

</p>

<p>where p is the activation rate coefficient. It is customary that p is called a rate constant, but, since the p stands for measure of the intensity of the stimulus causing the activation, p may be variable (non-constant).</p>

<p>More complete is an open system, namely, in its simplest form,</p>

<p>

<math display="inline" id="Tachyphylaxis:1">
 <semantics>
  <mrow>
   <mi>R</mi>
   <mover accent="true">
    <mo>→</mo>
    <mi></mi>
   </mover>
   <mi>A</mi>
   <mover accent="true">
    <mo>→</mo>
    <mrow>
     <mpadded lspace="10pt" width="+10pt">
      <mi>p</mi>
     </mpadded>
     <mrow>
      <mo stretchy="false">(</mo>
      <mi>S</mi>
      <mo stretchy="false">)</mo>
     </mrow>
    </mrow>
   </mover>
   <mi>B</mi>
   <mover accent="true">
    <mo>→</mo>
    <mrow>
     <mpadded lspace="10pt" width="+10pt">
      <mi>q</mi>
     </mpadded>
    </mrow>
   </mover>
   <mi></mi>
  </mrow>
  <annotation-xml encoding="MathML-Content">
   <apply>
    <and></and>
    <apply>
     <apply>
      <csymbol cd="latexml">absent</csymbol>
      <ci>normal-→</ci>
     </apply>
     <ci>R</ci>
     <ci>A</ci>
    </apply>
    <apply>
     <apply>
      <cerror>
       <csymbol cd="ambiguous">fragments</csymbol>
       <csymbol cd="unknown">p</csymbol>
       <cerror>
        <csymbol cd="ambiguous">fragments</csymbol>
        <ci>normal-(</ci>
        <csymbol cd="unknown">S</csymbol>
        <ci>normal-)</ci>
       </cerror>
       <ci>normal-</ci>
      </cerror>
      <ci>normal-→</ci>
     </apply>
     <share href="#.cmml">
     </share>
     <ci>B</ci>
    </apply>
    <apply>
     <apply>
      <cerror>
       <csymbol cd="ambiguous">fragments</csymbol>
       <csymbol cd="unknown">q</csymbol>
       <ci>normal-</ci>
      </cerror>
      <ci>normal-→</ci>
     </apply>
     <share href="#.cmml">
     </share>
     <csymbol cd="latexml">absent</csymbol>
    </apply>
   </apply>
  </annotation-xml>
  <annotation encoding="application/x-tex">
   R\xrightarrow{}A\xrightarrow{\ \ p(S)\ \ }B\xrightarrow{\ \ q\ \ }
  </annotation>
 </semantics>
</math>

</p>

<p>where <strong>R</strong> stands for the <em>rate of production</em> of <strong>A</strong>, <strong>p(S)</strong> is the <em>activation</em> rate coefficient explicitely expressing its dependence on the stimulus intensity <strong>S</strong> and <strong>q</strong> represents the rate coefficient of <em>removal</em> from the state <strong>B</strong>. In this elementaly open system the steady state of <strong>B</strong> always equal to <strong>R/q</strong>.</p>

<p>The above scheme is only the necessary condition for the rate sensitivity phenomenon, and other pathways of deactivation of B may be considered, with the subsequent return to the inactive form of the receptor/enzyme A. Examples<a class="footnoteRef" href="#fn3" id="fnref3"><sup>3</sup></a><a class="footnoteRef" href="#fn4" id="fnref4"><sup>4</sup></a><a class="footnoteRef" href="#fn5" id="fnref5"><sup>5</sup></a> offer particular use of such (mathematical) models in endocrinology, physiology and pharmacology.</p>
<h2 id="examples">Examples</h2>
<h3 id="hormone-replacement">Hormone replacement</h3>

<p><a href="Hormone_replacement_therapy_(menopause)" title="wikilink">Hormone replacement</a> when used in menopausal women in the form of estrogen and progesterone implants is cited as having potential to lead to tachyphylaxis, but that citation is based on a single study done in 1990<a class="footnoteRef" href="#fn6" id="fnref6"><sup>6</sup></a> and no follow-up research is available to support this interpretation.</p>
<h3 id="psychedelics">Psychedelics</h3>

<p>Psychedelics such as <a class="uri" href="LSD-25" title="wikilink">LSD-25</a> and <a class="uri" href="psilocybin" title="wikilink">psilocybin</a>-containing <a href="Psilocybin_mushrooms" title="wikilink">mushrooms</a> demonstrate very rapid tachyphylaxis. In other words, one may be unable to '<a href="psychedelic_experience" title="wikilink">trip</a>' two days in a row. Some people are able to 'trip' by taking up to three times the dosage, yet some users may not be able to negate tachyphylaxis at all until a period of days has gone by.</p>
<h3 id="centrally-acting-analgesics">Centrally acting analgesics</h3>

<p>In a patient fully withdrawn from centrally-acting analgesics, viz. opioids, going back to an intermittent schedule or maintenance dosing protocol, a fraction of the old tolerance level will rapidly develop, usually starting two days after opioid therapy is resumed and, in general, leveling off after day 7. Whether this is caused directly by opioid receptors modified in the past or effecting a change in some metabolic set-point is unclear. Increasing the dose will usually restore efficacy; relatively rapid opioid rotation may also be of use if the increase in tolerance continues.</p>
<h3 id="beta-2-agonists">Beta-2 agonists</h3>

<p>Inhalation of an agonist for the <a href="beta-2_adrenergic_receptor" title="wikilink">beta-2 adrenergic receptor</a>, such as <a href="Salbutamol,_Albuterol_(US)" title="wikilink">Salbutamol, Albuterol (US)</a>, is the most common treatment for <a class="uri" href="asthma" title="wikilink">asthma</a>. Polymorphisms of the beta-2 receptor play a role in tachyphylaxis. Expression of the Gly-16 allele (glycine at position 16) results in greater receptor downregulation by endogenous catecholamines at baseline compared to Arg-16. This results in a greater single-use bronchodilator response in individuals homozygous for Arg-16 compared to Gly-16 homozygotes.<a class="footnoteRef" href="#fn7" id="fnref7"><sup>7</sup></a> However, with regular beta-2 agonist use, asthmatic Arg-16 individuals experience a significant decline in bronchodilator response. This decline does not occur in Gly-16 individuals. It has been proposed that the tachyphylactic effect of regular exposure to exogenous beta-2 agonists is more apparent in Arg-16 individuals because their receptors have not been downregulated prior to agonist administration.<a class="footnoteRef" href="#fn8" id="fnref8"><sup>8</sup></a></p>
<h3 id="nicotine">Nicotine</h3>

<p><a class="uri" href="Nicotine" title="wikilink">Nicotine</a> may also show tachyphylaxis over the course of a day, although the mechanism of this action is unclear.<a class="footnoteRef" href="#fn9" id="fnref9"><sup>9</sup></a></p>
<h3 id="other-examples">Other examples</h3>
<ul>
<li><a href="Nitroglycerine_(pharmacology)" title="wikilink">Nitroglycerine</a> and other <a href="nitrovasodilator" title="wikilink">nitrovasodilators</a> of the nitrate type demonstrates tachyphylaxis, requiring drug-free intervals when administered transdermally</li>
<li>Repeated doses of <a class="uri" href="ephedrine" title="wikilink">ephedrine</a> may display tachyphylaxis, since it is an indirectly acting <a class="uri" href="sympathomimetic" title="wikilink">sympathomimetic</a> amine, which will deplete noradrenaline from the nerve terminal. Thus, repeated doses result in less noradrenaline released than the initial dose.</li>
<li><a class="uri" href="Hydralazine" title="wikilink">Hydralazine</a> displays tachyphylaxis if given as a monotherapy for antihypertensive treatment. It is administered with a beta-blocker with or without a diuretic.</li>
<li><a class="uri" href="Metoclopramide" title="wikilink">Metoclopramide</a> is another example.</li>
<li><a class="uri" href="Dobutamine" title="wikilink">Dobutamine</a>, a direct-acting <a href="beta_agonist" title="wikilink">beta agonist</a> used in <a href="congestive_heart_failure" title="wikilink">congestive heart failure</a>, also demonstrates tachyphylaxis.</li>
<li><a class="uri" href="Desmopressin" title="wikilink">Desmopressin</a> used in the treatment of <a href="von_Willebrand_disease" title="wikilink">type 1 von Willebrand disease</a> is, in general, given every 12–24 hours in limited numbers due to its tachyphylactic properties.</li>
<li><a class="uri" href="Caffeine" title="wikilink">Caffeine</a> has the potential to display tachyphylaxis if consumed in repeated high doses, such as the 30mg per 100ml of fluid common in many energy drinks.</li>
<li><a class="uri" href="Amphetamine" title="wikilink">Amphetamine</a></li>
<li><a class="uri" href="Ranitidine" title="wikilink">Ranitidine</a>, used for acid reflux treatment, can display rapid tachyphylaxis within six weeks of treatment initiation, limiting its long-term use potential.</li>
</ul>
<h2 id="intervention-and-reversal">Intervention and reversal</h2>
<h3 id="intranasal-decongestants">Intranasal decongestants</h3>

<p>Use of intranasal decongestants (such as oxymetazoline) for more than three days leads to tachyphylaxis of response and rebound congestion, caused by alpha-adrenoceptor mediated down-regulation and desensitization of response. Oxymetazoline-induced tachyphylaxis and rebound congestion are reversed by intranasal <a class="uri" href="fluticasone" title="wikilink">fluticasone</a>.<a class="footnoteRef" href="#fn10" id="fnref10"><sup>10</sup></a></p>
<h2 id="see-also">See also</h2>
<ul>
<li><a href="Desensitization_(medicine)" title="wikilink">Desensitization (medicine)</a></li>
<li><a href="Physiological_tolerance" title="wikilink">Physiological tolerance</a></li>
<li><a href="Physical_dependence" title="wikilink">Physical dependence</a></li>
<li><a class="uri" href="Mithridatism" title="wikilink">Mithridatism</a></li>
<li><a class="uri" href="Habituation" title="wikilink">Habituation</a></li>
</ul>
<h2 id="references">References</h2>
<h2 id="external-links">External links</h2>
<ul>
<li></li>
</ul>

<p>"</p>

<p><a class="uri" href="Category:Pharmacodynamics" title="wikilink">Category:Pharmacodynamics</a></p>
<section class="footnotes">
<hr/>
<ol>
<li id="fn1">Bunnel, Craig A. Intensive Review of Internal Medicine, Harvard Medical School 2009.<a href="#fnref1">↩</a></li>
<li id="fn2"><a href="#fnref2">↩</a></li>
<li id="fn3"><a href="#fnref3">↩</a></li>
<li id="fn4"><a href="#fnref4">↩</a></li>
<li id="fn5"><a href="#fnref5">↩</a></li>
<li id="fn6"><a href="#fnref6">↩</a></li>
<li id="fn7"><a href="#fnref7">↩</a></li>
<li id="fn8"><a href="#fnref8">↩</a></li>
<li id="fn9"><a href="#fnref9">↩</a></li>
<li id="fn10"><a href="#fnref10">↩</a></li>
</ol>
</section>
</hr></body>
</html>
